The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.
about
Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosisIntravenous immunoglobulin for the treatment of childhood encephalitisIntravenous immunoglobulin for Guillain-Barré syndromeIntravenous immunoglobulin for Guillain-Barré syndromeIntravenous immunoglobulin for juvenile idiopathic arthritisHow citation distortions create unfounded authority: analysis of a citation networkBiomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be ExploredBiologics in dermatology: an integrated reviewPredicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic NeuritisA case of deep vein thrombosis and pulmonary thromboembolism after intravenous immunoglobulin therapyAutoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.Therapeutic advances and future prospects in immune-mediated inflammatory myopathies.Intravenous immunoglobulin treatment in a patient with adrenomyeloneuropathyNovel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain-Barré syndrome.Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.New insights into neuromyelitis opticaBullous pemphigoid treatment review.Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders.The use of i.v. IG therapy in dermatology.Treatment strategies for myasthenia gravis.Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.Development of novel therapies for MG: Studies in animal models.Autoantibodies in neuromuscular autoimmune disorders.Neuromyelitis optica: potential roles for intravenous immunoglobulin.Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future.Drug-induced thrombosis: an update.Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations.Managing patients with side effects and adverse events to immunoglobulin therapy.Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trialImmune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity.Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy.Intravenous immunoglobulin for the treatment of childhood encephalitis.Severe periodontal disease associated with long-term treatment with intravenous immunoglobulin.Recommendations for the use of albumin and immunoglobulins.Long-term response of neuropathic pain to intravenous immunoglobulin in relapsing diabetic lumbosacral radiculoplexus neuropathy. A case report.IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety.Intravenous immunoglobulin for treatment of neuromuscular disease.Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies.Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis).Direct medical costs of liquid intravenous immunoglobulins in children, adolescents, and adults in Spain.
P2860
Q22251013-28C7FA4E-B1C2-4944-908B-6C426A044A81Q24192957-3458D243-94EF-4ADB-8D74-125D14566053Q24193522-120F387E-0001-40A1-9F35-E3DFAC7A8F96Q24202100-C06EF869-50D4-4280-B31C-52F6F78E2548Q24244815-37B0273C-7DFA-4459-ABAF-26A69E98089BQ24260685-2D1CE2A2-75BB-4E1C-9202-BC3AB97FAF38Q26785669-0AC84E7A-752E-46B9-9CD0-DC7FC3899F29Q27004638-3421DCD5-06BD-4876-8976-4D45412C5ABDQ27320796-6101C78F-3D19-48ED-B3A7-E03745F3EF94Q28220499-9277E16D-4976-4EB8-8EAF-BA80B99E62A2Q28264405-46C7D092-D253-46BC-B4C3-6ED123158701Q34409105-276EFB38-133C-4E02-AC8E-70D01E87D032Q34421075-57669F87-8B79-4255-804F-46B7722DA5AEQ34451654-C0024BA4-4DC8-447E-AFFB-62701908E1E8Q34620111-0671F3D1-2DF6-4A79-9E91-9125FBA8051BQ35539641-2A07ED2E-98C9-46A9-BF76-99577D81B9C3Q36655183-DD4F4821-B384-4B91-B8F2-7E968DDCB2A0Q36794149-16B85DFF-B94B-49A6-A0A4-2626AC4F8494Q36986054-6AE412A2-A048-485D-941B-EB42FB53BCBDQ37483922-4111B035-57C0-4063-9BFE-9A9F47A4B4EFQ37557375-BDE206B6-450B-4C06-9009-08066B5D1A8CQ37713733-68C8E0C1-7B09-4D32-BB80-62B162E28970Q37754738-008CEC5A-2D67-47D4-806E-CB3DFE7CA90BQ38043401-4C441220-714F-4E63-8223-9B36232C2CCDQ38068530-B05F632C-6C09-4BDF-AB85-65C2871D680FQ38103820-42DB55AD-A8A3-43F5-8590-415D3D1AF2BBQ38203801-E11983E8-7283-47FA-957B-2564279BFA7EQ38614953-F924074C-4C0E-494B-A1FF-60B6B28125F3Q38646013-B20D5230-F775-46FE-AF42-E64FE0E69CBBQ38842992-D6F1EBCE-5F13-405F-8298-3EE8F78311B7Q41834761-F3D0605A-0923-4D77-8A93-D3CA9C05D111Q41926851-B334E6EC-80D0-4667-A835-8734A7EED345Q41983427-B3F9F054-8A22-4A2A-B1E0-C9C391C78C18Q42671923-3243404C-4178-4BD6-89D8-2C5BBA09D8A7Q46336114-7B07B8D6-8EF8-4958-9205-EFB4B0C65C38Q49299297-DE6B89D0-0FFE-4C7D-BF3F-F1F2A7C881D8Q50133537-B0643C87-0936-4305-BFF3-3B4CC8300F55Q50197158-63CB8DE9-3AD1-4FB2-BD22-05D9A7128C28Q50895051-0B2C02E2-BBD5-4FA7-BCFA-1287F745BE8AQ51164170-5A439E46-929C-4BEA-B0BD-AB01140839D3
P2860
The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The use of intravenous immunog ...... ndications and safety profile.
@ast
The use of intravenous immunog ...... ndications and safety profile.
@en
type
label
The use of intravenous immunog ...... ndications and safety profile.
@ast
The use of intravenous immunog ...... ndications and safety profile.
@en
prefLabel
The use of intravenous immunog ...... ndications and safety profile.
@ast
The use of intravenous immunog ...... ndications and safety profile.
@en
P1476
The use of intravenous immunog ...... ndications and safety profile.
@en
P2093
Marinos C Dalakas
P304
P356
10.1016/J.PHARMTHERA.2004.04.002
P577
2004-06-01T00:00:00Z